ArticleInternational ophthalmology2025
The clinical outcomes of ultra-low-dose radiotherapy for primary conjunctival mucosa-associated lymphoid tissue lymphoma.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the treatment efficacy, long-term outcomes and ocular toxicity of ultra-low-dose radiotherapy (4 Gy) in managing conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.
methodsThis study retrospectively analyzed 15 patients with conjunctival MALT lymphoma between 2020 and 2022, who received 4 Gy radiotherapy (RT) delivered in consecutive 2-Gy fractions. The long-term outcomes included response rate, response time, recurrences or progression, and RT-related toxic effects.
resultsfifteen patients (eight males, seven females) all had histopathologically confirmed MALT lymphoma, which localized within unilateral or bilateral conjunctiva. At a median follow-up of 30 months (range, 9-48), complete response (CR) was observed in 89% of cases (n = 13) and partial response (PR) in 11% (n = 2), with a median time to CR of 2 months (range 1-12). Neither local nor distant recurrences were observed, and no disease progression occurred. There was no acute toxic effect in patients after RT. Only three patients developed mild dry eyes as a late treatment toxicity.
conclusionUltra-low-dose RT presented an outstanding therapeutic effect on conjunctival MALT lymphoma with acceptable toxicity. Further studies like randomized controlled clinical trials can provide more evidence for clinical management.
Indexed as
Identifiers
40576839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.